A phase I study of panobinostat in combination with gemcitabine in the treatment of solid tumors

Clinical Advances in Hematology and Oncology

Volumn 9, Issue 3, 2011, Pages 225-230

  Jones, Suzanne F ^a   Bendell, Johanna C ^a   Infante, Jeffrey R ^a   Spigel, David R ^a   Thompson, Dana S ^a   Yardley, Denise A ^a   Greco, F Anthony ^a   Murphy, Patrick B ^a   Burris, Howard A ^a  

^a SARAH CANNON RESEARCH INSTITUTE   (United States)

Author keywords

Gemcitabine; Histone deacetylase inhibitors; Myelosuppression; Panobinostat; Solid tumors

Indexed keywords

GEMCITABINE; PANOBINOSTAT;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTICLE; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPOPHOSPHATEMIA; LUNG NON SMALL CELL CANCER; MALE; MORNING DOSAGE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVARY CANCER; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL; PROSTATE CANCER; QT PROLONGATION; RASH; SOLID TUMOR; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; FEMALE; HUMANS; HYDROXAMIC ACIDS; MALE; MIDDLE AGED; NEOPLASMS; TREATMENT OUTCOME;

EID: 79953245914     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Glaser KB. HDAC inhibitors: clinical update and mechanism-based potential. Biochem Pharmacol. 2007;74:659-671.
2. Emanuele S, Lauricella M, Tesoriere G. Histone deacetylase inhibitors: apop-totic efects and clinical implications (review). Int J Oncol. 2008;33:637-646.
3. Piekarz RL, Bates SE. Epigenetic modifers: basic understanding and clinical development. Clin Cancer Res. 2009;15:3918-3926.
4. Qian DZ, Kato Y, Shabbeer S, et al. Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589. Clin Cancer Res. 2006;12:634-642.
5. Prince HM, Bishton MJ, Johnstone RW. Panobinostat (LBH589): a potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumors. Future Oncol. 2009;5:601-612.
6. Prince HM, Bishton MJ, Harrison SJ. Clinical studies of histone deacetylase inhibitors. Clin Cancer Res. 2009;15:3958-3969.
7. Haefner M, Bluethner T, Niederhagen M, et al. Experimental treatment of pancreatic cancer with two novel histone deacetylase inhibitors. World J Gastroenterol. 2008;14:3681-3692.
8. Atadja P. Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges. Cancer Lett. 2009;280:233-241.
9. Giles F, Fischer T, Cortes J, et al. A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res. 2006;12:4628-4635.
10. Dickinson M, Ritchie D, DeAngelo DJ, et al. Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin lymphoma. Br J Haematol. 2009;147:97-101.
11. Zhang L, Lebwohl D, Masson E, et al. Clinically relevant QTc prolongation is not associated with current dose schedules of LBH589 (panobinostat). J Clin Oncol. 2008;26:332-334.
12. Sharma S, Vogelzang NJ, Beck A, et al. Phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of LBH589, a novel deacetylase (DAC) inhibitor given intravenously on a new once weekly schedule. J Clin Oncol (ASCO Annual Meeting Proceedings Part I). 2007;25. Abstract 14109.
13. Prince HM, George D, Patnaik A, et al. Phase I study of oral LBH589, a novel deacetylase (DAC) inhibitor in advanced solid tumors and non-hodgkin's lymphoma. J Clin Oncol (ASCO Annual Meeting Proceedings Part I). 2007;25. Abstract 3500.
14. Ellis L, Pan Y, Smyth GK, et al. Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profles in cutaneous T-cell lymphoma. Clin Cancer Res. 2008;14:4500-4510.
15. Donadelli M, Costanzo C, Beghelli S, et al. Synergistic inhibition of pancreatic adenocarcinoma cell growth by trichostatin A and gemcitabine. Biochim Biophys Acta. 2007;1773:1095-1106.
16. Rundall BK, Denlinger CE, Jones DR. Suberoylanilide hydroxamic acid combined with gemcitabine enhances apoptosis in non-small cell lung cancer. Surgery. 2005;138:360-367.
17. Fuino L, Bali P, Wittmann S, et al. Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B. Mol Cancer Ter. 2003;2:971-984.
18. Schniewind B, Heintz K, Kurdow R, et al. Combination phenylbutyrate/ gemcitabine therapy efectively inhibits in vitro and in vivo growth of NSCLC by intrinsic apoptotic pathways. J Carcinog. 2006;5:25.
19. Piacentini P, Donadelli M, Costanzo C, et al. Trichostatin A enhances the response of chemotherapeutic agents in inhibiting pancreatic cancer cell proliferation. Virchows Arch. 2006;448:797-804.
20. Kanzaki M, Kakinuma H, Kumazawa T, et al. Low concentrations of the histone deacetylase inhibitor, depsipeptide, enhance the efects of gemcitabine and docetaxel in hormone refractory prostate cancer cells. Oncol Rep. 2007;17:761-767.
21. Arnold NB, Arkus N, Gunn J, Korc M. Te histone deacetylase inhibitor sube-roylanilide hydroxamic acid induces growth inhibition and enhances gemcitabine-induced cell death in pancreatic cancer. Clin Cancer Res. 2007;13:18-26.
22. Terasse P, Arbuck SG, Eisenhauer AE, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000;92:205-216.
23. Weber HA, Tai F, Paul S, et al. QT interval measurements in patients with hematologic malignancies and solid tumors treated with oral panobinostat (LBH589). Blood (ASH Annual Meeting Abstracts). 2009;114. Abstract 3781.